Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Yale University University of Minnesota Forest Laboratories |
---|---|
Information provided by: | Yale University |
ClinicalTrials.gov Identifier: | NCT00585169 |
The goal of the proposed study is to evaluate the efficacy and safety of the drug memantine in individuals with pathological gambling (PG). Thirty subjects with DSM-IV PG will receive 10 weeks of open-label treatment with memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with PG. We hypothesize that memantine will reduce the severity of gambling symptoms and improve patients' overall functioning. This study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Condition | Intervention | Phase |
---|---|---|
Pathological Gambling |
Drug: Memantine Hydrochloride |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Open-Label Multi-Center Trial of Memantine (Namenda(TM)) Treatment of Pathological Gambling |
Estimated Enrollment: | 30 |
Study Start Date: | December 2007 |
Estimated Study Completion Date: | December 2011 |
Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 21 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jennifer D. Bellegarde, New Haven, CT | (203) 974-7072 | jennifer.bellegarde@yale.edu |
Contact: Brian L. Odlaug, Minneapolis, MN | (612) 627-4363 | odla0019@umn.edu |
United States, Connecticut | |
Yale University School of Medicine | Active, not recruiting |
New Haven, Connecticut, United States, 06519 | |
United States, Minnesota | |
University of Minnesota Medical Center, Fairview | Recruiting |
Minneapolis, Minnesota, United States, 55454 | |
Contact: Brian L. Odlaug 612-627-4363 odla0019@unm.edu | |
Contact: Jon E. Grant, MD, JD, MPH 612-273-9736 grant045@umn.edu |
Principal Investigator: | Marc N. Potenza, M.D, Ph.D. | Yale University |
Responsible Party: | Yale University School of Medicine ( Marc Potenza, M.D., Ph.D. Principal Investigator ) |
Study ID Numbers: | 0705002703*, HIC 0705002703 |
Study First Received: | December 25, 2007 |
Last Updated: | February 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00585169 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Pathological Gambling Compulsive Gambling Gambling Addiction Gambling |
Treatment Memantine Pharmacology |
Excitatory Amino Acids Neurotransmitter Agents Impulse Control Disorders Behavior, Addictive Dopamine |
Gambling Mental Disorders Memantine Dopamine Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Antiparkinson Agents Excitatory Amino Acid Agents Pharmacologic Actions Impulse Control Disorders |
Gambling Mental Disorders Therapeutic Uses Memantine Dopamine Agents Central Nervous System Agents Excitatory Amino Acid Antagonists |